Pulmatrix Overview
- Year Founded
-
2003
- Status
-
Public
- Employees
-
2
- Stock Symbol
-
PULM
- Investments
-
2
- Share Price
-
$1.30
- (As of Friday Closing)
Pulmatrix General Information
Description
Pulmatrix Inc is a biopharmaceutical company focused on the development of novel inhaled therapeutic products intended to prevent and treat migraine and respiratory diseases with important unmet medical needs using its patented dry powder delivery technology, iSPERSE. Its pipeline of clinical assets includes PUR3100 for the treatment of acute migraine, PUR1800 for the treatment of acute exacerbations of chronic obstructive pulmonary disease (AECOPD), and PUR1900 for the treatment of ABPA in patients with asthma and in patients with cystic fibrosis (CF).
Contact Information
Website
www.pulmatrix.comCorporate Office
- 945 Concord Street
- Suite 1217
- Framingham, MA 01701
- United States
Corporate Office
- 945 Concord Street
- Suite 1217
- Framingham, MA 01701
- United States
Pulmatrix Stock Performance
As of 13-Nov-2026, Pulmatrix’s stock price is $1.30. Its current market cap is $4.71M with 3.65M shares.
(As of Friday Closing)
| Stock Price | Previous Close | 52 wk Range | Market Cap | Shares | Average Volume | EPS |
|---|---|---|---|---|---|---|
| $1.30 | $1.30 | $1.06 - $4.98 | $4.71M | 3.65M | 32.3K | -$1.10 |
Pulmatrix Financials Summary
As of 30-Jun-2026, Pulmatrix has a trailing 12-month revenue of null.
|
In Thousands, USD |
TTM 30-Jun-2026 | FY 2025 31-Dec-2025 | FY 2024 31-Dec-2024 | FY 2023 31-Dec-2023 |
|---|---|---|---|---|
| EV | 3,835 | 3,351 | 14,711 | (5,922) |
| Revenue | 0 | 0 | 7,806 | 7,298 |
| EBITDA | (4,085) | (5,306) | (9,591) | (13,513) |
| Net Income | (4,013) | (5,162) | (9,559) | (14,121) |
| Total Assets | 3,246 | 4,139 | 9,943 | 33,958 |
| Total Debt | 0 | 0 | 0 | 8,756 |
Pulmatrix Valuation & Funding
| Deal Type | Date | Amount | Valuation/ EBITDA |
Post-Val | Status | Debt |
|---|
Pulmatrix Cap Table
| Stock | # of Shares Authorized |
Par Value | Dividend Rate (%) | Original Issue Price |
Liquidation | Liquidation Pref. Multiple |
Conversion Price |
% Owned |
|---|
Pulmatrix Comparisons
Industry
Financing
Details
Pulmatrix Competitors (27)
One of Pulmatrix’s 27 competitors is Verona Pharma, a Corporate Backed or Acquired company based in London, United Kingdom.
| Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
|---|---|---|---|---|---|---|
| Verona Pharma | Corporate Backed or Acquired | London, United Kingdom | ||||
| Enterprise Therapeutics | Venture Capital-Backed | Brighton, United Kingdom | ||||
| Aqualung Therapeutics | Venture Capital-Backed | Tucson, AZ | ||||
| Spero Therapeutics | Formerly VC-backed | Cambridge, MA | ||||
| Melinta Therapeutics | Private Equity-Backed | Parsippany, NJ |
Pulmatrix Related Research & Analysis
Explore institutional-grade private market research from our team of analysts.
-
Verticals
Pulmatrix Patents
Pulmatrix Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| AU-2023334713-A1 | Methods of using itraconazole dry powders | Pending | 31-Aug-2022 | ||
| EP-4580632-A2 | Methods of using itraconazole dry powders | Pending | 31-Aug-2022 | ||
| US-20260335305-A1 | Methods of using itraconazole dry powders | Pending | 31-Aug-2022 | ||
| WO-2024049982-A2 | Methods of using itraconazole dry powders | Inactive | 31-Aug-2022 | ||
| WO-2024049982-A3 | Methods of using itraconazole dry powders | Inactive | 31-Aug-2022 | A61P31/10 |
Pulmatrix Signals
Growth Rate
Growth
Size Multiple
Key Data Points
Similarweb Unique Visitors
Majestic Referring Domains
Pulmatrix Investors
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds | Contact Info |
|---|
Pulmatrix Acquisitions (2)
Pulmatrix’s most recent deal was a Reverse Merger with Eos SENOLYTIX. The deal was made on 26-Mar-2026.
| Company Name | Deal Date | Deal Type | Deal Size | Industry | Lead Partner |
|---|---|---|---|---|---|
| Eos SENOLYTIX | 26-Mar-2026 | Reverse Merger | Drug Discovery | ||
| Ruthigen | 15-Jun-2015 | Merger/Acquisition | Drug Delivery |
Pulmatrix ESG
Risk Overview
Risk Rating
Updated November, 04, 2026
41.93 | Severe Risk
Risk Scale
A lower score indicates better sustainability
Negl
0-10
Low
10-20
Med
20-30
High
30-40
Severe
40+
Exposure
Exposure refers to the extent to which a company is exposed to different material ESG issues
Management
Management is related to actions taken to manage ESG issues
Peers Analysis
Peer performance insights compare the company’s ESG performance to the performance of selected peers to help inform future ESG decisions and drive internal performance improvements.
Global
Covered Companies
of 13,585
Rank
Percentile
Pharmaceuticals
Industry
of 852
Rank
Percentile
Pharmaceuticals
Subindustry
of 354
Rank
Percentile
Pulmatrix FAQs
-
When was Pulmatrix founded?
Pulmatrix was founded in 2003.
-
Where is Pulmatrix headquartered?
Pulmatrix is headquartered in Framingham, MA.
-
What is the size of Pulmatrix?
Pulmatrix has 2 total employees.
-
What industry is Pulmatrix in?
Pulmatrix’s primary industry is Biotechnology.
-
Is Pulmatrix a private or public company?
Pulmatrix is a Public company.
-
What is Pulmatrix’s stock symbol?
The ticker symbol for Pulmatrix is PULM.
-
What is the current stock price of Pulmatrix?
As of 13-Nov-2026 the stock price of Pulmatrix is $1.30.
-
What is the current market cap of Pulmatrix?
The current market capitalization of Pulmatrix is $4.71M.
-
Who are Pulmatrix’s competitors?
Verona Pharma, Enterprise Therapeutics, Aqualung Therapeutics, Spero Therapeutics, and Melinta Therapeutics are some of the 27 competitors of Pulmatrix.
-
What is Pulmatrix’s annual earnings per share (EPS)?
Pulmatrix’s EPS for 12 months was -$1.10.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process
